Phreesia’s (PHR) “Market Perform” Rating Reiterated at Citizens Jmp

Phreesia (NYSE:PHR)‘s stock had its “market perform” rating reaffirmed by equities research analysts at Citizens Jmp in a research note issued to investors on Wednesday.

A number of other analysts have also issued reports on PHR. DA Davidson dropped their target price on Phreesia from $35.00 to $30.00 and set a “buy” rating on the stock in a research report on Friday, January 23rd. Mizuho reduced their price target on Phreesia from $22.00 to $19.00 and set an “outperform” rating for the company in a report on Tuesday, March 24th. Royal Bank Of Canada began coverage on Phreesia in a research note on Friday, January 9th. They set a “moderate buy” rating and a $26.00 price objective for the company. Canaccord Genuity Group dropped their price objective on Phreesia from $33.00 to $22.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $16.00 target price (down from $24.00) on shares of Phreesia in a research report on Tuesday. Twelve equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Phreesia currently has a consensus rating of “Moderate Buy” and an average target price of $22.00.

Phreesia Price Performance

PHR opened at $8.33 on Wednesday. Phreesia has a twelve month low of $7.77 and a twelve month high of $32.76. The firm has a market cap of $502.28 million, a price-to-earnings ratio of 277.70 and a beta of 0.67. The company has a current ratio of 2.44, a quick ratio of 2.44 and a debt-to-equity ratio of 0.01. The company has a fifty day simple moving average of $12.36 and a 200 day simple moving average of $17.57.

Phreesia (NYSE:PHR) last issued its quarterly earnings data on Monday, March 30th. The company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.05). The firm had revenue of $127.07 million during the quarter, compared to analyst estimates of $126.75 million. Phreesia had a return on equity of 3.33% and a net margin of 0.48%.The business’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.11) EPS. Equities research analysts expect that Phreesia will post -1.1 EPS for the current fiscal year.

Insider Buying and Selling at Phreesia

In other Phreesia news, insider David Linetsky sold 6,106 shares of Phreesia stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total value of $103,863.06. Following the completion of the transaction, the insider owned 231,723 shares of the company’s stock, valued at $3,941,608.23. The trade was a 2.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Evan Roberts sold 6,317 shares of the business’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total transaction of $107,452.17. Following the sale, the insider owned 834,632 shares of the company’s stock, valued at approximately $14,197,090.32. The trade was a 0.75% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 70,358 shares of company stock worth $1,123,569. Company insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Phreesia

A number of institutional investors have recently modified their holdings of the business. Federated Hermes Inc. acquired a new stake in Phreesia during the third quarter worth about $32,000. Van ECK Associates Corp lifted its holdings in Phreesia by 78.7% in the fourth quarter. Van ECK Associates Corp now owns 2,502 shares of the company’s stock worth $42,000 after acquiring an additional 1,102 shares during the last quarter. Asset Management One Co. Ltd. acquired a new position in Phreesia in the third quarter valued at approximately $45,000. Rockefeller Capital Management L.P. boosted its stake in Phreesia by 354.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 2,755 shares of the company’s stock valued at $47,000 after acquiring an additional 2,149 shares during the period. Finally, KBC Group NV grew its holdings in shares of Phreesia by 83.4% during the fourth quarter. KBC Group NV now owns 3,449 shares of the company’s stock valued at $58,000 after purchasing an additional 1,568 shares during the last quarter. Institutional investors own 92.10% of the company’s stock.

Key Phreesia News

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Company reached profitability and strong cash‑flow milestones (positive GAAP net income, +$78.8M operating cash, >$50M free cash flow, and >$100M adjusted EBITDA) alongside ~16% y/y revenue growth, supporting a longer‑term recovery thesis. Business Wire: Q4 results
• Positive Sentiment: Some shop-side analysts kept constructive ratings (e.g., Stephens remains overweight with a $20 PT; other firms maintain buy/outperform stances despite lower targets), signaling pockets of analyst support for a rebound. Benzinga: analyst actions
• Neutral Sentiment: Full earnings and call transcripts are available for investors digging into management commentary and the detail behind the guide cut (useful for assessing timing of client spend recovery). Earnings call transcript
• Negative Sentiment: Phreesia cut FY27 revenue guidance to $510–$520M (from $545–$559M), citing reduced visibility into pharma client spending and weaker-than-expected second‑half commitments; this is the primary catalyst for the selloff. Benzinga: guidance cut
• Negative Sentiment: Investors punished the stock after the quarter: reported EPS missed one set of consensus estimates (and media reported a sharp post‑earnings decline), triggering heavy selling and headlines about a ~25–30% intraday drop. Investing.com: shares tumble
• Negative Sentiment: Multiple firms lowered price targets and re-priced risk: examples include JPMorgan ($16 PT), BMO ($14), Needham ($14), Canaccord ($22), Truist ($11), Robert W. Baird and Citi (both $10), increasing near‑term analyst uncertainty. Benzinga: analyst PT cuts

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.